A Two-arm Randomized Non-comparative Phase 2 Trial of AGEN2034 (anti PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
